Beckley Execs Talk Phase 2b Data, Competition, and Phase 3 Plans

5-MeO-DMT Phase 2b results for treatment-resistant depression (TRD) drive a CEO and CMO interview about Beckley Psytechs next development steps. The discussion centers on intranasal BPL-003 dosing, including why the 8 mg dose can outperform 12 mg in efficacy and tolerability, and what the team learned about durability and a single-dose dose range. Beckley also connects subjective effects to clinical outcomes, focusing on Mystical Experience Questionnaire (MEQ) subdomains like ineffability as a potential predictor of depression benefit. The interview further covers how psychological support is handled across Beckley and GH Research programs, compares expectations versus GH Research Phase 2b, and lays out Phase 3 design considerations, including IP position and a potential faster regulatory path.